补肾活血祛痰法预防兔激素性股骨头坏死的实验研究
|
摘要
1研究目的
随着激素在临床广泛应用,激素性股骨头坏死(SONFH)发病率有上升的趋势。该病是骨科临床的疑难病,病因病机复杂,缺乏公认有效的治疗手段。中医药治疗SONFH有一定效果,但其优势在于预防和早期的治疗,对于中晚期SONFH,单纯应用中药治疗效果欠佳。在临床上研究中药预防应用激素的高危人群的SONFH发病存在一些困难。本研究的目的是研究补肾活血祛痰中药组方健骨方在预防家兔SONFH中的效果和作用机制,为临床研究的开展提供实验依据和理论支持。
2研究方法
将30只健康SPF级新西兰家兔,按体重均衡原则随机分成4组：即正常组、模型组、补肾活血祛痰组方健骨方低剂量组(简称中药低剂量组)、健骨方高剂量组(简称中药高剂量组)。正常组6只,模型组、中药低剂量组、中药高剂量组各8只。
正常对照组予灌胃等剂量生理盐水10ml／kg；中药低级量组予每天灌胃健骨方混悬液(含生药3.6g／kg／d)。中药高剂量组予每天灌胃健骨方混悬液(含生药7.19g／kg／d)；连续用药3周后,模型组、中药低剂量组、中药高剂量组均选择在左侧大腿内侧肌肉注射甲基泼尼龙琥珀酸钠20mg／kg／d一次,再连续用药3周。在实验开始3周后抽血查各组血脂三项、血液流变学进行检测,离心取部分血清置于—70℃的低温冰箱备用待检测骨保护素(osteoprotegerin,OPG)和破骨细胞分化因子(receptoractivactivatorofunclear factor kappa B ligand, RANKL);肌肉注射甲基泼尼龙琥珀酸钠造模3周后,再予以查各组血脂三项、血液流变学。连同造模前所取血清标本一起采用酶联免疫吸附试验法(ELISA)检测血清骨保护素(OPG)和破骨细胞分化因子(RANKL);并处死家兔,剖取右后侧股骨头,10%福尔马林溶液固定,进行制片、HE染色及病理组织学检查：把制作好的HE染色切片置于光学显微镜下,从低倍到高倍,参照Matsui病理分级方法观察骨髓、骨小梁有无坏死。
采用Image-Pro Plus 6.0软件计算股骨头坏死面积及坏死率。其余数据采用SPSS18.0统计软件包进行统计。各组数据采用均数±标准差(x±S)表示,各组比较用单因素方差分析(one-way ANOVA),组间比较采用S-N-K法进行两两比较。变量间的相关性采用Spearman秩相关分析统计。以P<0.05为显著性差异,P<0.01为非常显著性差异。
3研究结果
3.1一般情况：中药低剂量组死亡1只,为灌胃操作方法失误,导致药液误入气道急性窒息而死；模型组造模后死亡2只。
3.2血脂水平比较：造模前：各组血清高密度脂蛋白(HDL)、胆固醇(TCHO)、甘油三脂水平对比,F=0.733,P=0.542>0.05；S-N-K法组间两两比较亦无显著性差异(P>0.05),具有可比性。造模后：①各组血清HDL水平对比：F=2.534,P=0.082>0.05；S-N-K法组间两两比较提示：模型组血清HDL水平低于正常组,有显著性差异(P=0.042<0.05),低于中药高剂量组,有显著性差异(P=0.018<0.05)；②各组血清TCHO水平对比：F=0.458,P=0.714>0.05；S-N-K法组间两两比较亦无显著性差异；③各组血清TRIG水平对比：F=5.041,P=0.008<0.01；S-N-K法组间两两比较提示：模型组明显高于正常组,有非常显著性差异(P=0.001<0.01)；高于中药低剂量组(P=0.019<0.05),高于中药高剂量组(P=0.013<0.05),有显著性差异。
3.2血流变学水平比较：造模前：各组血流变学指标对比：P>0.05,S-N-K法组间两两比较亦无显著性差异(P>0.05),具有可比性。造模后：①全血粘度值切变率：中药低剂量组与模型组全血粘度值切变率(200、30、5、1)对比无显著性差异(P>0.05)；模型组全血粘度值切变率(200、30、5、1)明显高于正常组(P<0.05),有非常显著性差异；模型组全血粘度值切变率200高于正常组(P<0.05),有显著性差异,全血粘度值切变率(30、5、1)明显高于正常组(P<0.01),有非常显著性差异；中药低剂量组全血粘度值切变率200高于正常组(P<0.05),有显著性差异,全血粘度值切变率(30、5、1)明显高于正常组(P<0.01),有非常显著性差异；②红细胞压积：模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药高剂量组高于正常组,有显著性差异(P=0.017<0.05)；与模型组对比：中药低剂量组无显著性差异(P=0.306>0.05),中药高剂量组明显低于模型组,有非常显著性差异(P=0.007<0.01)；③血浆粘度值切变率200：模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组高于正常组,有显著性差异(P=0.012<0.05),中药高剂量组无显著性差异(P=0.070>0.05)；与模型组对比：中药低剂量组无显著性差异(P=0.142>0.05),中药高剂量组(P=0.020<0.05),有显著性差异；④各组全血低切相对粘度对比：模型组高于正常组、中药低剂量组和中药高剂量组,有显著性差异(P<0.05)；⑤全血高切相对粘度对比：模型组明显高于正常组、中药低剂量组和模型组,有非常显著性差异(P<0.01)；⑥其余各组红细胞刚性指数、红细胞聚集指数、红细胞变形指数、全血高切还原粘度、全血低切还原粘度对比(P>0.05),无统计学意义。3.3血清OPG、RANKL、OPG/RANKL水平比较：造模前：各组血清OPG水平对比：F=0.046,P>0.05；各组血清RANKL浓度对比：F=0.844,P=0.483>0.05；各组OPG/RANKL对比：F=0.89,P=0.459>0.05。S-N-K法组间两两比较亦无显著性差异。说明造模前各组动物OPG、RANKL、OPG/RANKL水平对比无显著性差异,具有可比性。造模后：①血清OPG水平对比：F=6.667,P=0.002<0.01；模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组和中药高剂量组低于正常组,有显著性差异(P<0.05)；中药低剂量组高于模型组,有显著性差异(P=0.026<0.05)；中药高剂量组高于模型组,有显著性差异(P=0.034<0.05)。②各组血清RANKL浓度对比：F=0.616,P=0.612>0.05；S-N-K法组间两两比较亦无显著性差异。③各组OPG/RANKL对比：模型组明显低于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组低于正常组,有显著性差异(P=0.011<0.05)；中药高剂量组明显高于正常组,有非常显著性差异(P=0.002<0.01)；中药低剂量组明显高于模型组,有非常显著性差异(P=0.001<0.01)；中药高剂量组明显高于模型组,有非常显著性差异(P=0.002<0.01)。
3.4股骨头病理表现结果：①正常组：6例病理正常,符合0级病变；模型组：造模后死亡2例,6例病理学改变符合2级病变；中药低剂组：灌胃死亡1例,1例病理学改变符合2级病变,6例病理学改变符合1级病变；中药高剂组：1例病理学改变符合2级病变,7例病理学改变符合1级病变。②造模后模型组股骨头坏死面积和坏死率明显高于正常组、中药低剂量组、中药高剂量组(P<0.01),有非常显著性差异。
3.5血清OPG、RANKL、OPG/RANKL与股骨头病理表现相关性分析：血清OPG水平与股骨头坏死面积的相关系数是-0.638,P=0.00<0.01,二者有负相关关系；血清RANKL水平与股骨头坏死面积的相关系数是0.131,P=0.516>0.05,无显著性差异；OPG/RANKL与股骨头坏死面积的相关系数是-0.636,P=0.00<0.01,二者有负相关关系；血清OPG水平与股骨头坏死率的相关系数是-0.673,P=0.00<0.01,二者有负相关关系；血清RANKL水平与股骨头坏死面积的相关系数是0.142,P=0.479>0.05,无显著性差异；OPG/RANKL与股骨头坏死率的相关系数是-0.638,P=0.000<0.01,二者有负相关关系。
4研究结论
4.1单纯肌注大剂量甲基波尼松龙造家兔SONFH模型,方法简单易行,形成周期短,动物死亡率低。
4.2激素可导致兔血脂代谢紊乱,血液流变学异常,可能导致兔OPG、OPG/RANKL降低,上调破骨细胞的活性,促进骨吸收,导致骨小梁断裂,发生激素性股骨头坏死。
4.3补肾活血祛痰中药组方健骨方可预防兔激素诱导的股骨头坏死的发生。
4.4补肾活血祛痰组方健骨方高剂量组、低剂量对应用激素的兔的血脂代谢紊乱和血液流变学异常、血液粘稠度增加,具有明显改善作用,高剂量组的作用更明显。该方药可能通过改善激素引起的血脂代谢紊乱、血流变学异常来预防SONFH。
4.5补肾活血健脾祛痰组方健骨方对激素导致的血OPG水平下降、OPG/RANKL降低有改善作用,有助于抑制破骨细胞功能,促进成骨,增加骨强度,防治骨坏死和塌陷的发生。
1 Objective:
With the mass use of clinical application of hormone, the trend of SONFH is increasing. SONFH is a difficult and complicate disease as its pathogenesis is not clear and lack of certain effective treatment approach for SONFH. Traditional Chinese medicine shows superiority in terms of prevention and treatment. But to the advanced SONFH, it's unsatisfactory when simply uses traditional Chinese medicine. To study the therapeutic effects and mechanism of the prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu on rabbit's SONFH prevention.
2 Methods
30 healthy SPF New Zealand rabbits were randomly allotted to 4 groups by weight:normal group (6 rabbits), the model group (8 rabbits), the prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu group (8 rabbits High-dosage group group for short), and the prescription of Jian Gu group (8 rabbits Low-dosage group group for short).
The normal control group was intragastrically perfused with saline of the same volume as 10 ml per kilogram at the same time. Low-dosage group were intragastrically perfused with suspension of prescription of Jian Gu with same volume (effective components is 3.6g/kg/d); and High-dosage group is 7.19g/kg/d. After gavage for 3 weeks, the model group, Low-dosage group and High-dosage group were injected sodium succinate methylprednisolone on the internal side of left leg 20mg/kg each time for another 3weeks. After the experiment for 3 weeks, physical examination such as TC, TG, HDL and hemorrheological changes were collected for detection. Part of the centrifugal blood kept on the -70℃would be test for OPG and RANKL. After injected by sodium succinate methylprednisolone for 3 weeks, TC, TG, HDL and hemorrheological changes were be measured again. All the blood samples were determined for OPG and RANKL by enzyme linked immunosorbent assay (ELISA) especially include the sample before modeling; and killed the rabbits, took the right posterior femoral head, which fixed formalin then observed pathologically with frost slice techniques and Sudan staining. It was observed under light microscopy from lower power to higher power according to Matsui grades to measure if the marrow and bone trabeculae were necorsis.
Date was tested with Image-Pro Plus 6.0 software to calculate the rate and square of necrosis of femoral head. The rest of the date was tested with SPSS18.0 software. The results were measured by ((?)±S). mean comparison in groups was conducted with single factor variance analysis, and the pairwise comparison was performed with S-N-K method. Correlation between the variable was deal with Spearman. There is statistical significance when P<0.05, and a very significant difference when P<0.01.
3 Results
3.1 The general result:One rabbit was died as faulty intragastrically method to block the tracheobronchial and made acute asphyxia in the Low-dosage group group. And 2 rabbits were died after modling.
3.2 Compare between blood lipids level:HDL、TCHO and TG blood level before the experiment is F=0.733, P=0.542>0.05;there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05), which shows comparable. After the experiment:①compare between each group in the level of HDL:F=2.534, P=0.082>0.05; the pairwise comparison with S-N-K method shows that:the HDL blood level in the model group was lower than normal group and had a statistical significance (P=0.042<0.05); the HDL blood level in the model group was lower than High-dosage group and had a statistical significance (P=0.018<0.05).②compare between each group in the level of TCHO, F=0.458, P=0.714>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05).③compare between each group in the level of TRIG:F=5.041, P=0.008<0.01; the pairwise comparison with S-N-K method shows that:the TRIG blood level in the model group was higher than normal group and had a very statistical significance (P=0.001<0.01); higher than low-dosage group (P=0.019<0.05) and high-dosage group (P=0.013 <0.05).
3.3 Compare between hemorrheological changes:index of hemorrheological changes before the experiment is P>0.05, there is no statistical significance in the pairwise comparison with S-N-K methodwhich shows comparable. After the experiment:①compare between each group in the level of whole blood viscosity: there was no statistical significance(P>0.05) between low-dosage group and model group;model group was much higher than normal group (P<0.01); blood viscosity 200 of model group was higher than High-dosage group (P<0.05); blood viscosity. (30、5、1) of model group was much higher than High-dosage (P<0.01);blood viscosity 200 of Low-dosage group was higher than normal group (P<0.05);blood viscosity (30、5、1) of Low-dosage group was much higher than normal group (P<0.01).②compare between each group in the level of TCHO: F=0.458, P=0.714>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05).③compare between each group in the level of TRIG:F=5.041, P=0.008<0.01; the pairwise comparison with S-N-K method shows that:the TRIG blood level in the model group was higher than normal group and had a very statistical significance (P=0.001<0.01); and higher than low-dosage group (P=0.019<0.05) and high-dosage group (P=0.013<0.05); The low-dosage group was lower than normal group in hemorrheological changes, there was a very statistical significance between two groups.
3.4 Compare between OPG、RANKL、OPG/RANKL:OPG、RANKL、OPG/RANKL blood level before the experiment is F=0.046, P>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P> 0.05), which shows comparable. After the experiment:①compare between each group in the level of OPG:F=6.667, P=0.002<0.01; the pairwise comparison with S-N-K method shows that:the OPG blood level in the model group was much lower than normal group and had a very statistical significance (P=0.000<0.01); was lower than Low-dosage group and had a statistical significance (P=0.026<0.05); and was lower than High-dosage group and had a statistical significance (P=0.034< 0.05); the OPG blood level in Low-dosage group and High-dosage group was lower than normal group and had a statistical significance (P<0.05).②compare between each group in the level of RANKL:F=0.616, P=0.612>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P> 0.05), which shows comparable.③ompare between each group in the level of OPG/RANKL:F=14.146, P=0.000<0.01;the pairwise comparison with S-N-K method shows that:the OPG/RANKL in the model group was much lower than normal group、Low-dosage group and High-dosage group and had a very statistical significance (P<0.01); the OPG/RANKL level in Low-dosage group and High-dosage group was lower than normal group and had a very statistical significance (P<0.01)
3.5 Pathology of femoral head:①ormal group:all of the 6 femoral head pathology were normal with 0 grade pathology;model group:2 rabbits were died after modling, the other 6 femoral head pathology were 2 grade pathology;Low-dosage group:1 femoral head pathology was 2 grade pathology and 6 femoral head pathology were 1 grade; pathology high-dosage group:1 femoral head pathology was 2 grade pathology and 7 femoral head pathology were 1 grade.②the necrotic area and necrotic rate of normal group were much higher than the other three groups and had a very statistical significance (P<0.01).
3.6 Correlation analysis between OPG、RANKL、OPG/RANKL in blood and pathology of femoral head:there is negative correlation between OPG and necrotic area (R=-0.638, P=0.00<0.01) and has much statistical significance; there is no correlation between RANKL and necrotic area (R=0.131, P=0.516>0.05) and has no statistical significance;there is negative correlation between OPG/RANKL and necrotic area (R=-0.636, P=0.00< 0.01) and has much statistical significance;there is negative correlation between OPG and necrotic rate (R=-0.673, P=0.00<0.01) and has much statistical significance; there is no correlation between RANKL and necrotic rate (R=0.142, P=0.479>0.05) and has no statistical significance; there is negative correlation between OPG/RANKL and necrotic rate (R=-0.638, P=0.000< 0.01) and has much statistical significance.
4 Conclusion
4.1 Model of SONFH by injected sodium succinate methylprednisolone on the rabbit is an easy way. Because it could shorter the production cycle and decrease the mortality of the rabbit.
4.2 Hormone would cause abnormal blood lipid metabolisom and blood rheology, which lead to decrease the level of OPG. OPG/RANKL in rabbit. Also it could increase the activity of osteoclasts and bring down the activity of the osteoblast-like cells so that cause SONFH happen.
4.3 Prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu can prevent rabbit's SONFH happened.
4.4 In the experiment, both the high-dosage group and low-dosage group can obviously improve the abnormal blood lipid, hemorrheological changes and blood viscosity. And the hight dosage, the more effect in the experiment. Maybe it would prevent SONFH through improving the abnormal blood lipid, hemorrheological changes cause by hormone.
4.5 Prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu can improve the OPG, low level of OPG/RANKL in the blood which was caused by hormone. It could help to bring down the activity of osteoclast and increase the osteoblast in order to strength the density of the bone and prevent the bone collapsed and degraded.
随着激素在临床广泛应用,激素性股骨头坏死(SONFH)发病率有上升的趋势。该病是骨科临床的疑难病,病因病机复杂,缺乏公认有效的治疗手段。中医药治疗SONFH有一定效果,但其优势在于预防和早期的治疗,对于中晚期SONFH,单纯应用中药治疗效果欠佳。在临床上研究中药预防应用激素的高危人群的SONFH发病存在一些困难。本研究的目的是研究补肾活血祛痰中药组方健骨方在预防家兔SONFH中的效果和作用机制,为临床研究的开展提供实验依据和理论支持。
2研究方法
将30只健康SPF级新西兰家兔,按体重均衡原则随机分成4组：即正常组、模型组、补肾活血祛痰组方健骨方低剂量组(简称中药低剂量组)、健骨方高剂量组(简称中药高剂量组)。正常组6只,模型组、中药低剂量组、中药高剂量组各8只。
正常对照组予灌胃等剂量生理盐水10ml／kg；中药低级量组予每天灌胃健骨方混悬液(含生药3.6g／kg／d)。中药高剂量组予每天灌胃健骨方混悬液(含生药7.19g／kg／d)；连续用药3周后,模型组、中药低剂量组、中药高剂量组均选择在左侧大腿内侧肌肉注射甲基泼尼龙琥珀酸钠20mg／kg／d一次,再连续用药3周。在实验开始3周后抽血查各组血脂三项、血液流变学进行检测,离心取部分血清置于—70℃的低温冰箱备用待检测骨保护素(osteoprotegerin,OPG)和破骨细胞分化因子(receptoractivactivatorofunclear factor kappa B ligand, RANKL);肌肉注射甲基泼尼龙琥珀酸钠造模3周后,再予以查各组血脂三项、血液流变学。连同造模前所取血清标本一起采用酶联免疫吸附试验法(ELISA)检测血清骨保护素(OPG)和破骨细胞分化因子(RANKL);并处死家兔,剖取右后侧股骨头,10%福尔马林溶液固定,进行制片、HE染色及病理组织学检查：把制作好的HE染色切片置于光学显微镜下,从低倍到高倍,参照Matsui病理分级方法观察骨髓、骨小梁有无坏死。
采用Image-Pro Plus 6.0软件计算股骨头坏死面积及坏死率。其余数据采用SPSS18.0统计软件包进行统计。各组数据采用均数±标准差(x±S)表示,各组比较用单因素方差分析(one-way ANOVA),组间比较采用S-N-K法进行两两比较。变量间的相关性采用Spearman秩相关分析统计。以P<0.05为显著性差异,P<0.01为非常显著性差异。
3研究结果
3.1一般情况：中药低剂量组死亡1只,为灌胃操作方法失误,导致药液误入气道急性窒息而死；模型组造模后死亡2只。
3.2血脂水平比较：造模前：各组血清高密度脂蛋白(HDL)、胆固醇(TCHO)、甘油三脂水平对比,F=0.733,P=0.542>0.05；S-N-K法组间两两比较亦无显著性差异(P>0.05),具有可比性。造模后：①各组血清HDL水平对比：F=2.534,P=0.082>0.05；S-N-K法组间两两比较提示：模型组血清HDL水平低于正常组,有显著性差异(P=0.042<0.05),低于中药高剂量组,有显著性差异(P=0.018<0.05)；②各组血清TCHO水平对比：F=0.458,P=0.714>0.05；S-N-K法组间两两比较亦无显著性差异；③各组血清TRIG水平对比：F=5.041,P=0.008<0.01；S-N-K法组间两两比较提示：模型组明显高于正常组,有非常显著性差异(P=0.001<0.01)；高于中药低剂量组(P=0.019<0.05),高于中药高剂量组(P=0.013<0.05),有显著性差异。
3.2血流变学水平比较：造模前：各组血流变学指标对比：P>0.05,S-N-K法组间两两比较亦无显著性差异(P>0.05),具有可比性。造模后：①全血粘度值切变率：中药低剂量组与模型组全血粘度值切变率(200、30、5、1)对比无显著性差异(P>0.05)；模型组全血粘度值切变率(200、30、5、1)明显高于正常组(P<0.05),有非常显著性差异；模型组全血粘度值切变率200高于正常组(P<0.05),有显著性差异,全血粘度值切变率(30、5、1)明显高于正常组(P<0.01),有非常显著性差异；中药低剂量组全血粘度值切变率200高于正常组(P<0.05),有显著性差异,全血粘度值切变率(30、5、1)明显高于正常组(P<0.01),有非常显著性差异；②红细胞压积：模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药高剂量组高于正常组,有显著性差异(P=0.017<0.05)；与模型组对比：中药低剂量组无显著性差异(P=0.306>0.05),中药高剂量组明显低于模型组,有非常显著性差异(P=0.007<0.01)；③血浆粘度值切变率200：模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组高于正常组,有显著性差异(P=0.012<0.05),中药高剂量组无显著性差异(P=0.070>0.05)；与模型组对比：中药低剂量组无显著性差异(P=0.142>0.05),中药高剂量组(P=0.020<0.05),有显著性差异；④各组全血低切相对粘度对比：模型组高于正常组、中药低剂量组和中药高剂量组,有显著性差异(P<0.05)；⑤全血高切相对粘度对比：模型组明显高于正常组、中药低剂量组和模型组,有非常显著性差异(P<0.01)；⑥其余各组红细胞刚性指数、红细胞聚集指数、红细胞变形指数、全血高切还原粘度、全血低切还原粘度对比(P>0.05),无统计学意义。3.3血清OPG、RANKL、OPG/RANKL水平比较：造模前：各组血清OPG水平对比：F=0.046,P>0.05；各组血清RANKL浓度对比：F=0.844,P=0.483>0.05；各组OPG/RANKL对比：F=0.89,P=0.459>0.05。S-N-K法组间两两比较亦无显著性差异。说明造模前各组动物OPG、RANKL、OPG/RANKL水平对比无显著性差异,具有可比性。造模后：①血清OPG水平对比：F=6.667,P=0.002<0.01；模型组明显高于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组和中药高剂量组低于正常组,有显著性差异(P<0.05)；中药低剂量组高于模型组,有显著性差异(P=0.026<0.05)；中药高剂量组高于模型组,有显著性差异(P=0.034<0.05)。②各组血清RANKL浓度对比：F=0.616,P=0.612>0.05；S-N-K法组间两两比较亦无显著性差异。③各组OPG/RANKL对比：模型组明显低于正常组,有非常显著性差异(P=0.000<0.01),中药低剂量组低于正常组,有显著性差异(P=0.011<0.05)；中药高剂量组明显高于正常组,有非常显著性差异(P=0.002<0.01)；中药低剂量组明显高于模型组,有非常显著性差异(P=0.001<0.01)；中药高剂量组明显高于模型组,有非常显著性差异(P=0.002<0.01)。
3.4股骨头病理表现结果：①正常组：6例病理正常,符合0级病变；模型组：造模后死亡2例,6例病理学改变符合2级病变；中药低剂组：灌胃死亡1例,1例病理学改变符合2级病变,6例病理学改变符合1级病变；中药高剂组：1例病理学改变符合2级病变,7例病理学改变符合1级病变。②造模后模型组股骨头坏死面积和坏死率明显高于正常组、中药低剂量组、中药高剂量组(P<0.01),有非常显著性差异。
3.5血清OPG、RANKL、OPG/RANKL与股骨头病理表现相关性分析：血清OPG水平与股骨头坏死面积的相关系数是-0.638,P=0.00<0.01,二者有负相关关系；血清RANKL水平与股骨头坏死面积的相关系数是0.131,P=0.516>0.05,无显著性差异；OPG/RANKL与股骨头坏死面积的相关系数是-0.636,P=0.00<0.01,二者有负相关关系；血清OPG水平与股骨头坏死率的相关系数是-0.673,P=0.00<0.01,二者有负相关关系；血清RANKL水平与股骨头坏死面积的相关系数是0.142,P=0.479>0.05,无显著性差异；OPG/RANKL与股骨头坏死率的相关系数是-0.638,P=0.000<0.01,二者有负相关关系。
4研究结论
4.1单纯肌注大剂量甲基波尼松龙造家兔SONFH模型,方法简单易行,形成周期短,动物死亡率低。
4.2激素可导致兔血脂代谢紊乱,血液流变学异常,可能导致兔OPG、OPG/RANKL降低,上调破骨细胞的活性,促进骨吸收,导致骨小梁断裂,发生激素性股骨头坏死。
4.3补肾活血祛痰中药组方健骨方可预防兔激素诱导的股骨头坏死的发生。
4.4补肾活血祛痰组方健骨方高剂量组、低剂量对应用激素的兔的血脂代谢紊乱和血液流变学异常、血液粘稠度增加,具有明显改善作用,高剂量组的作用更明显。该方药可能通过改善激素引起的血脂代谢紊乱、血流变学异常来预防SONFH。
4.5补肾活血健脾祛痰组方健骨方对激素导致的血OPG水平下降、OPG/RANKL降低有改善作用,有助于抑制破骨细胞功能,促进成骨,增加骨强度,防治骨坏死和塌陷的发生。
1 Objective:
With the mass use of clinical application of hormone, the trend of SONFH is increasing. SONFH is a difficult and complicate disease as its pathogenesis is not clear and lack of certain effective treatment approach for SONFH. Traditional Chinese medicine shows superiority in terms of prevention and treatment. But to the advanced SONFH, it's unsatisfactory when simply uses traditional Chinese medicine. To study the therapeutic effects and mechanism of the prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu on rabbit's SONFH prevention.
2 Methods
30 healthy SPF New Zealand rabbits were randomly allotted to 4 groups by weight:normal group (6 rabbits), the model group (8 rabbits), the prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu group (8 rabbits High-dosage group group for short), and the prescription of Jian Gu group (8 rabbits Low-dosage group group for short).
The normal control group was intragastrically perfused with saline of the same volume as 10 ml per kilogram at the same time. Low-dosage group were intragastrically perfused with suspension of prescription of Jian Gu with same volume (effective components is 3.6g/kg/d); and High-dosage group is 7.19g/kg/d. After gavage for 3 weeks, the model group, Low-dosage group and High-dosage group were injected sodium succinate methylprednisolone on the internal side of left leg 20mg/kg each time for another 3weeks. After the experiment for 3 weeks, physical examination such as TC, TG, HDL and hemorrheological changes were collected for detection. Part of the centrifugal blood kept on the -70℃would be test for OPG and RANKL. After injected by sodium succinate methylprednisolone for 3 weeks, TC, TG, HDL and hemorrheological changes were be measured again. All the blood samples were determined for OPG and RANKL by enzyme linked immunosorbent assay (ELISA) especially include the sample before modeling; and killed the rabbits, took the right posterior femoral head, which fixed formalin then observed pathologically with frost slice techniques and Sudan staining. It was observed under light microscopy from lower power to higher power according to Matsui grades to measure if the marrow and bone trabeculae were necorsis.
Date was tested with Image-Pro Plus 6.0 software to calculate the rate and square of necrosis of femoral head. The rest of the date was tested with SPSS18.0 software. The results were measured by ((?)±S). mean comparison in groups was conducted with single factor variance analysis, and the pairwise comparison was performed with S-N-K method. Correlation between the variable was deal with Spearman. There is statistical significance when P<0.05, and a very significant difference when P<0.01.
3 Results
3.1 The general result:One rabbit was died as faulty intragastrically method to block the tracheobronchial and made acute asphyxia in the Low-dosage group group. And 2 rabbits were died after modling.
3.2 Compare between blood lipids level:HDL、TCHO and TG blood level before the experiment is F=0.733, P=0.542>0.05;there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05), which shows comparable. After the experiment:①compare between each group in the level of HDL:F=2.534, P=0.082>0.05; the pairwise comparison with S-N-K method shows that:the HDL blood level in the model group was lower than normal group and had a statistical significance (P=0.042<0.05); the HDL blood level in the model group was lower than High-dosage group and had a statistical significance (P=0.018<0.05).②compare between each group in the level of TCHO, F=0.458, P=0.714>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05).③compare between each group in the level of TRIG:F=5.041, P=0.008<0.01; the pairwise comparison with S-N-K method shows that:the TRIG blood level in the model group was higher than normal group and had a very statistical significance (P=0.001<0.01); higher than low-dosage group (P=0.019<0.05) and high-dosage group (P=0.013 <0.05).
3.3 Compare between hemorrheological changes:index of hemorrheological changes before the experiment is P>0.05, there is no statistical significance in the pairwise comparison with S-N-K methodwhich shows comparable. After the experiment:①compare between each group in the level of whole blood viscosity: there was no statistical significance(P>0.05) between low-dosage group and model group;model group was much higher than normal group (P<0.01); blood viscosity 200 of model group was higher than High-dosage group (P<0.05); blood viscosity. (30、5、1) of model group was much higher than High-dosage (P<0.01);blood viscosity 200 of Low-dosage group was higher than normal group (P<0.05);blood viscosity (30、5、1) of Low-dosage group was much higher than normal group (P<0.01).②compare between each group in the level of TCHO: F=0.458, P=0.714>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P>0.05).③compare between each group in the level of TRIG:F=5.041, P=0.008<0.01; the pairwise comparison with S-N-K method shows that:the TRIG blood level in the model group was higher than normal group and had a very statistical significance (P=0.001<0.01); and higher than low-dosage group (P=0.019<0.05) and high-dosage group (P=0.013<0.05); The low-dosage group was lower than normal group in hemorrheological changes, there was a very statistical significance between two groups.
3.4 Compare between OPG、RANKL、OPG/RANKL:OPG、RANKL、OPG/RANKL blood level before the experiment is F=0.046, P>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P> 0.05), which shows comparable. After the experiment:①compare between each group in the level of OPG:F=6.667, P=0.002<0.01; the pairwise comparison with S-N-K method shows that:the OPG blood level in the model group was much lower than normal group and had a very statistical significance (P=0.000<0.01); was lower than Low-dosage group and had a statistical significance (P=0.026<0.05); and was lower than High-dosage group and had a statistical significance (P=0.034< 0.05); the OPG blood level in Low-dosage group and High-dosage group was lower than normal group and had a statistical significance (P<0.05).②compare between each group in the level of RANKL:F=0.616, P=0.612>0.05; there is no statistical significance in the pairwise comparison with S-N-K method (P> 0.05), which shows comparable.③ompare between each group in the level of OPG/RANKL:F=14.146, P=0.000<0.01;the pairwise comparison with S-N-K method shows that:the OPG/RANKL in the model group was much lower than normal group、Low-dosage group and High-dosage group and had a very statistical significance (P<0.01); the OPG/RANKL level in Low-dosage group and High-dosage group was lower than normal group and had a very statistical significance (P<0.01)
3.5 Pathology of femoral head:①ormal group:all of the 6 femoral head pathology were normal with 0 grade pathology;model group:2 rabbits were died after modling, the other 6 femoral head pathology were 2 grade pathology;Low-dosage group:1 femoral head pathology was 2 grade pathology and 6 femoral head pathology were 1 grade; pathology high-dosage group:1 femoral head pathology was 2 grade pathology and 7 femoral head pathology were 1 grade.②the necrotic area and necrotic rate of normal group were much higher than the other three groups and had a very statistical significance (P<0.01).
3.6 Correlation analysis between OPG、RANKL、OPG/RANKL in blood and pathology of femoral head:there is negative correlation between OPG and necrotic area (R=-0.638, P=0.00<0.01) and has much statistical significance; there is no correlation between RANKL and necrotic area (R=0.131, P=0.516>0.05) and has no statistical significance;there is negative correlation between OPG/RANKL and necrotic area (R=-0.636, P=0.00< 0.01) and has much statistical significance;there is negative correlation between OPG and necrotic rate (R=-0.673, P=0.00<0.01) and has much statistical significance; there is no correlation between RANKL and necrotic rate (R=0.142, P=0.479>0.05) and has no statistical significance; there is negative correlation between OPG/RANKL and necrotic rate (R=-0.638, P=0.000< 0.01) and has much statistical significance.
4 Conclusion
4.1 Model of SONFH by injected sodium succinate methylprednisolone on the rabbit is an easy way. Because it could shorter the production cycle and decrease the mortality of the rabbit.
4.2 Hormone would cause abnormal blood lipid metabolisom and blood rheology, which lead to decrease the level of OPG. OPG/RANKL in rabbit. Also it could increase the activity of osteoclasts and bring down the activity of the osteoblast-like cells so that cause SONFH happen.
4.3 Prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu can prevent rabbit's SONFH happened.
4.4 In the experiment, both the high-dosage group and low-dosage group can obviously improve the abnormal blood lipid, hemorrheological changes and blood viscosity. And the hight dosage, the more effect in the experiment. Maybe it would prevent SONFH through improving the abnormal blood lipid, hemorrheological changes cause by hormone.
4.5 Prescription includes supplement kidney, invigorate blood and dispel phlegm and prescription of Jian Gu can improve the OPG, low level of OPG/RANKL in the blood which was caused by hormone. It could help to bring down the activity of osteoclast and increase the osteoblast in order to strength the density of the bone and prevent the bone collapsed and degraded.
引文
[1]刘少军,袁浩.股骨头坏死的中医临床思路与方法探讨[J].中国医药学报,2002,17(1)：44-47.
[2]曾平,韦标方,展磊,等.何伟教授运用“治未病”理论指导股骨头坏死防治经验介绍[J].新中医,2009,41(1)：7.
[3]陈卫衡,许锐,欧彤文,等.中药预防激素性股骨头坏死临床初步研究[J],北京中医药,2008,27(10)：761-763.
[4]庞智辉.股骨头前外侧柱与激素性股骨头坏死预后和保魏疗效的相关性研究[J].广州中医药大学博士论文,2008.
[5]陈卫衡.股骨头坏死“痰瘀同治”的理论基础[J].江苏中医药,2008,40(5)：3-4.
[6]Pietrogrande V, Mastromarino R. Osteopatda prolungata trattamento corti sonico[J].Orthop Traum Appar Mat,1957,25:791-810.
[7]Jones JP, jr. Etiology and pathogenesis of Osteonecrosis[J]. Clin orthop, 1994,14:153.
[8]马在山.马氏中医治疗股骨头坏死[M].北京：人民卫生出版社,1996.116.
[9]刘铁钢,陈卫衡.非创伤性股骨头坏死的流行病学研究[J].当代医学,2008,14(24)：64-65.
[10]李子荣,孙伟,屈辉,等.皮质类固醇与骨坏死关系的临床研究[J].中华外科杂志2005,43(16)：1048-1053.
[11]陈卫衡,张强,刘道兵.SARS并发股骨头坏死的发病特点分析及临床意义[J].中国骨伤,2004,7(7)：338-340.
[12]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[13]Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy[J]. Diabetes Metab Res Rev,2003,19(Supp 11):2-8.
[14]Weinstein RS,Jilka RL, Parfitt AM, etal. Inhibition of osteoblastogenesis and Prorootion of apoptosis of osteoblasts and osteoeytes by glueeeorti-coids. Potential mechanisms of their deleterious efects on bone[J].J Clin Invest,1998,102(2):274-282.
[15]Hemigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem cell pool in the proximal femur in corticosteroid-induced osteonecrosis[J]. J Bone Joint Surs Br.1999,81(2):349-355.
[16]LiX, Jin L, Cui Q,et al. Steroid effects on osteogenesis through mesenc hymal cell gene expression[J]. Osteoporos Int.2004,15:1.
[17]Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis[J]. Clin Orthop.2000,370:295-310.
[18]Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glu cocorticoid-induced osteonecrosis of the hip[J].J Clin Endocrinol Metab. 2000,85 (8):2907-2912.
[19]曾小军,杨述华,禹志宏.辛伐他汀联合阿仑磷酸钠预防兔激素性股骨头坏死[J],郧阳医学院学报,2009,28(3)：237-243.
[20]黄昌林,杨卫强.兔激素性股骨头坏死早期骨组织细胞功能改变及外敷中药的治疗作用观察[J].解放军医学杂志,2009,34(5)：501-503.
[21]Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine t hat regulates osteoclast differentiation and activation[J]. Cell,1998,93: 165-176
[22]Hofbauer LC, Gorl F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocoticoid-induced osteoporosis[J]. Endoerinologi,1999,140:4382-4389.
[23]王岩,迟志永,韩纲.激素性骨坏死骨质丢失与骨保护蛋白表达的相关研究[J].中华外科杂志,2002,7：534-537.
[24]王建忠,王坤正,时志斌,等.长期应用糖皮质激素对大鼠股骨头骨组织OPG/RANKL mRNA表达的影响[J].西安交通大学学报,2008,29(6)：630-632.
[25]Jones JP. Intravaseular coagulation and osteonecrosis[J]. Clin Orthop, 1992,277:41.
[26]Kawai K, Tamaki A, Hirohata H, et al. Steroid2induced accumulation o f lipid in the osteocytes of the rabbit femoral head. A histochemical an d electron microscop ic study [J].J Bone Joint Surg Am,1985,67(5):755-76 3.
[27]薛元锁,时述山,李亚非,等.激素性股骨头坏死病程中骨形态发生蛋白-2的改变及意义[J].中华实验外科杂志,2000,17(5)：455-456.
[28]周谋望,秦建中,刘志雄,等.降脂药物防治激素所致股骨头骨细胞损害的实验研究[J].中华医学杂志,1996,76(1)：13-15.
[29]周谋望,秦建中,朱盛修.激素导致股骨头骨细胞损害的研究[J].中华实验外科杂志,1994,11(2)：89-90.
[30]吴洪娟,郭文君,王亦进,等.激素诱发兔股骨头坏死的组织学及超微结构观察[J].解剖科学进展,2003,9(1)：23-24.
[31]Yin L, LI YB, Wang YS. Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures:mechanism of steroid-induced osteonecrosis[J]. Chin Med J,2006,119(7):581-588.
[32]张义福,刘建,孟国林,等.兔激素性股骨头坏死病程中肝脂肪酶改变的意义[J].第四军医大学学报,2006,27(8)：737-740.
[33]Asano T, Takahashi KA, Fujioka M, Inoue S, Satomi Y, Nishino H, Tanaka T, Hirota Y, Takaoka K, Nakajima S, Kubo T Genetic analysis of steroid-induced osteonecrosis of the femoral head [J]. Orthop Sci.2003,8(3):329-333.
[34]刘德宝,卜海富,桂斌捷.大剂量激素诱导建立兔股骨头缺血性坏死模型[J].中国组织工程研究与临床康复,2009,13(2)：284-287.
[35]童培建,肖鲁伟,季卫锋,等.脂质代谢及破骨细胞活性在激素性股骨头坏死塌陷发生过程中的作用研究[J].中国骨伤,2009,22(2)：110-113
[36]Jones Jp. Fat embolisms, intravascular coagulation, and osteonecrosis[J]. Clin Othop,1993,292:294-308
[37]Jones LC, Mont MA, Le TB,et al. Procoagulants and osteonecrosis[J]. Rheu matol,2003,30(4):783.
[38]KoromPilias AV,Ortel TL, Uthaniak JR. Coagulation abnormalities in Patients with hip osteonecrosis[J]. orthop Clin North Am.2004,35(3):265-271.
[39]Wolf Drescher, Karen P, Weigert, et al. Fermoral head blood flow reducti on and hypercoagulablitity under 24 hmegadose steroidtreatment in pigS [J].J orthopaedic Research.2004,22:501-508.
[40]Tsantarliotou MP, Taitzoglou IA, Goulas P, et al. Dexamethasone reduees acrosin activity of ram spermatozoa[J]. Andrologia.2002,34(3):188-193.
[41]Halleux CM, Declerek PJ, Tran SL,et al. Hormonal control of plasminogen activator in hibitor-1 gene expression and produecion in human adipose tissue:stimulation by glucocorticoids and inhibition by catecholamines[J]. J Clin Endocrinol Metab.1999,84(11):4097-4105.
[42]Shimojo M, Miyachi Y. Hyperlipidemia and glucocorticoid[J]. Nippon Rins ho.2001,59 Supp13:220-222.
[43]Perera M, Sattar N, Petrie JR, et al. The effects of transdermal estradi ol incombination with oral norethisterone on lipoproteins, coagulation, an d endothelial markers in postmenopausal Women with type 2 diabetes:arand omized, plaeebo-controlled study[J].J Clin Endocrinol Metab.2001,86(3):11 40-1143.
[44]Ichiseki T, Matsumoto T,Nishino M, et al.oxidative stress and vascular permeability in steroid-induced osteonecrosis model[J].J orthop Sci.2004, 9(5):509-515.
[45]Wallwork CJ, Parks DA, Sehmid-Sehonbein GW. Xanthine oxidase activity i n the dexamethasone-induced hypertensive rat[J]. Microvasc Res.2003,66(1): 30-37.
[46]Vogt CJ, Schmid-Schonbein GW. Microvascular endothelial cell death and rarefaction in the gluecocorticoid-induced hypertensive rat[J]. Mierocir culation.2001,8(2):129-139.
[47]李子荣,孙伟,屈辉,等.皮质类固醇与骨坏死关系的临床研究.中华外科杂志[J],2005,43(16)：1048-1053
[48]Asano T, Takahashi KA, Fujioka M, et al.ABCBI C3435T and G2677T/A Po lymorphism decreased the risk for steroid-induced osteonecrosis of the f emoral head after kidney transplantation[J]. Pharmacogenetics.2003,13(1 1):675-682.
[49]Zalavras CG, Vartholomatos G, Dokou E, Malizos KN Genetic background of osteonecrosis:associated with thrombophilic mutations?[J]. Clin Orth op.2004,422:251-255.
[50]Ferrari, P; Sehroeder V;Anderson S et al. Association of plasminogen aetivator inhibitor-1 genotyPe with avaseular osteonecrosis in steroid-treated renal allograft recipients[J]. TransPlantation.2002,74(8):1147-11 52.
[51]Bjorkman A, Svensson PJ, Hillarp A, et al. Faetor V leiden and Prothrombin genemution:risk factors for osteonecrosis of the femoral head in adults[J]. ClinorthoP.2004,425:168-172.
[52]Murata M. Genetic polymorphisms assoeiated with thrombotic disorders in Japanese poPulation [J]. Fibrinolyis & Proteolysis.2000,14:155.
[53]Asano T, Takallashi KA, Fujioka M. Relationship between postrenal tra nsplant osteonecrosis of the feromal head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects [J]. T ransplantatation.2004,77(2):220-225.
[54]何伟,李可大.激素性股骨头坏死的遗传易感性研究[J].中国骨与关节外科,3009.2(4)：284-289.
[55]Ueo T, Tsutsumi Syamamuro T, et al. Biomechanical aspect of the development of aseptic necrosis of the femoral head[J].Arch Orthop Trauma Surg,1985, 104(3):145-149.
[56]Mihara K,Hiranmo T. Standing is a causative factor in osteonecrosis o f the femoral head in growing rats[j].Joumal of pediatric orthopaedics,1 998,18 (5):665-669.
[57]Iwasaki K, Hirano T, Sagara K, et al. Idiopathic necrosis of the femoral Epiphyseal nucleus in rats[J].Clin Orthop,1992,31-40.
[58]Suehiro M, Hirano T, Mihara K, et al.Etiologic factors in femoral head Osteonecrosis in growing rats[J]. OrthopSci,2000,5:52-6.
[59]王金熙,董天华,陈贤志,等.实验性股骨头缺血性坏死修复过程的生物力学研究[J].中华外科杂志,1993,31(6)：374
[60]Magnussen RA, Guilak F, Vail TP, Cartilage degenration in post-collapse case of osteonecrosis of the human femoral head:altered mechanical properties in tension compression and shear[J], J Orthop Res,2005,23:576-583.
[61]Jones JP. Intravascular coagulation and osteonecrosis[J]. Clin Or. thop, 1992,277:41.
[62]Saito S, Ohzono K, Ono K. Early arteriopathy and postulated pathogenesis of the femoral head[J]. Clin Orthop,1992,277:98.
[63]Atsumi T, Yoshikatsr K. Role of blood supply of the femoral head in the pathogenesis of idiopathic osteonecrosis[J]. Clin Orthop,1992,277:22.
[64]Wang GJ, Cui Q. The Pathogenesis Of Steroid-Induced Osteonecrosis and the Effect of Lipid Clearing Agents on this Mechanism [A]Ur baniak JR, Jones Jr JP. Osteonecrosis. Vo122. Rosemont. IL American. Orthopaedic Association and American Academy of Orthopaedic Surgeons.1997,22:159-166.
[65]Hirano K, Tsutsui H, Sugioka Y, et al. Histopathologic alterations of retinacular vessels and osteonecrosis[J]. Clin Orthop,1997,342:192.
[66]Nishimura T, Matsumoto T, Nishino M, et al. Histopatbologic study of veins in steroid treated rabbits[J]. Clin Orthop,1997,334:37.
[67]郑召民,董大华.非刨伤性骨坏死血管内凝血学说研究的进展[J].中华骨科杂志,1998,18(10)：627.
[68]姚永东,王国毓,杨毓华,等.激素性股骨头坏死动物血液流变学的观察[J].中医正骨,2000,12(4)：6-7.
[69]李峻辉,宁亚功,叶建红,等.激素性股骨头坏死家兔血液流变学及血脂观察[J].云南医药,2003,24(2)：82-84.
[70]胡长根,陈君长,刘强,等.激素对股骨头微血管及组织细胞的影响[J].中华骨科杂志,2004,24(6)：359.
[71]洪嵩,张天宏.非创伤性股骨头坏死模型的血液流变学及脂质代谢[J].遵义医 学院学报,2009,32(2)：136-138.
[72]胡长根,陈君长,贺西京,等.激素性股骨头坏死与血液流变学变化的关系[J].西安交通大学学报(医学版),2003,24(6)：595-598.
[73]李月白.激素诱导骨髓基质细胞成脂分化的实验研究[J].中华骨科杂志,1999,19(11)：687-689.
[74]Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin lig and and inhibition of osteoprotegerin production by glucocorticoids in h uman osteoblastic lincage cells:potential paracrine mechanisms of glucoc orticoid-induced osteopomsis[J]. Endocrinology,1999,140:4382-4389.
[75]童培建,肖鲁伟,季卫锋,等.脂质代谢及破骨细胞活性在激素性股骨头坏死塌陷发生过程中的作用研究[J].中国骨伤,2009,22(2)：110-113.
[76]Cui Q, Wang CJ, Balian C. Steroid induced adipogenesis pluripotential cell line from bone marrow[J]. J Bone Joint Surg(Am),1997,79:1054-1063.
[77]0reffo RO, Virdi AS, Triffiu JT. Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures [J]. Eur J Cell Biol, 1997,74:251-261.
[78]薛元锁,时述山,李亚非,等.激素性股骨头坏死病程中骨形态发生蛋白-2的改变及其意义[J].中华实验外科杂志,2000,17(5)：455.
[79]Hemigou P, Beaujean F Treatment of osteonecrosis with autologous bone marrow grafting [J]. Clin Orthop.2002,405:14-23.
[80]Gang ji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells [J]. A pilot study. J Bone Joint Surg Am.2004,86-A(6):1153-1160.
[81]Valentin-Opran A, Wozney J, Csimma C, et al. Clinical evaluation of recombinant human bone morphogenetic protein-2 [J]. Clin Orthop.2002,395: 110-120.
[82]梅荣成,杨述华,杨操,等.钛合金支撑架结合自体骨和DBM治疗股骨头坏死[J].中国矫形外科杂志,2006,14(7)：509-51.
[83]LiX, Cui Q, Kao C, Wang GJ, Balian Glovastatin inhibits adipogenic an d stimulates osteogenic differentiation by suppressing PRARgamma2 and in creasing Cbfal/Runx2 cxpression in bone marrow mesenehymal cell cultures [J]. Bone.2003,33(4):652-659.
[84]Cui Q, Wang GJ, Su CC, Balian G The Otto Aufranc Award. Lovastatin pr events steroid induced adipogenesis and osteonecrosis[J]. Clin Orthop.1 997,344:8-19.
[85]Pritchett JW Statin therapy decreases the risk of osteonecrosis in p atients receiving steroids [J].Clin Orthop.2001,386:173-178.
[86]曾小军,杨述华,禹志宏.辛伐他汀联合阿仑磷酸钠预防兔激素性股骨头坏死[J],郧阳医学院学报,2009,28(3)：237-243.
[87]王卫东,廖文胜,王义生.辛伐他汀预防激素性股骨头坏死的实验研究[J].郑州大学学报(医学版),2004,39(3)：473-475.
[88]周谋望,秦建中,刘志雄,等.降脂药物防治激素所致股骨头骨细胞损害的实验研究[J].中华医学杂志,1996,76(1)：13-16.
[89]Glueck CJ, Freiberg RA, Wang P. Role of thrombosis in osteoneerosis[J]. CurrHematol Rep.2003,2(5):417-422.
[90]Glueek CJ, Freiberg RA, Fontaine RN, et al. Anticoagulant therapy fo r osteonecrosis associated with heritable hypofibrinolysis and thromboph ilia [J] Expert Opin Investig Drugs.2001,10(7):1309-1316.
[91]Norman D, Miller Y, Sabo E, et al. The effects of enoxaparin on the reparative Processes in experimental osteonecrosis of the femoral head of the rat [J]. APMIS.2002,110(3):221-228.
[92]刘万林,郭文通,李文琪,等.抗凝改善骨内微循环治疗激素性股骨头缺血性坏死的初步观察[J1.内蒙古医学院学报,1999,21(4)：235-256.
[93]廖文胜,王义生,高远,等.激素性股骨头坏死发病机制及藻酸双酯钠的干预作用[J].河南医药信息,2001,9(10)：1-3.
[94]李卫哲,李景南,张新.抗凝药物预防激素所致股骨头坏死[J].吉林大学学报(医学版),2003,29(4)：475-476.
[95]Masuhara K, Nakata K, Yamasaki S, et al. Involvement of plateletN activation in experimental osteonecrosis in rabbits[J]. Int J Exp Pathol,2001,82(5): 303-308.
[96]李卫哲,李景南,张新.抗凝药物预防激素所致股骨头坏死[J].吉林大学学报(医学版),2003,29(4)：475-476.
[97]Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid Induced oste onecrosis of femoral head in systemic lupuserythematosus by anticoagulan t[J]. Lupus,2006,15(6):354-357.
[98]Lauber S. High energy extracorporeal shockwave therapy in femur head necrosis[J].Z Orthop Ihre Grenzgeb.2000,138(5):3-4.
[99]Ludwig J, Lauber S, Lauber HJ, et al. High-energy shock wave treatment of femoral head necrosis in adults [J].Clin Orthop.2001,387:119-126.
[100]Trock DH. Electromagnetic fields and magnets. Investigational treatment for musculoskeletal disorders [J], Rheum Dis Clin North Am.2000,26(1):51-62.
[101]Kim HJ. Comrnent on:Hyperbaric oxygen therapy as a treatment for st age-Iavascular necrosis of the femoral head [J]. J Bone Joint Surg Br.20 04,86(1):150-151.
[102]Reis ND, Schwartz 0, Militianu D, et al. Hyperbaric oxygen therapy as a treatment for stage-I avaseular necrosis of the femoral head [J]. J Bone Joint Surg Br.2003,85(3):371-375.
[103]Seber S, Omerogiu H, Cetlnkanat H, et al. The efficacy of pulsed elect romagnetic fields used alone in the treatment of femoral head osteonecro sis:a report of two cases [J]. Acta Orthop Traumatol Turc.2003,37(5):41 0-413.
[104]Agarwala S, Sule A, Pai BU, et al. Alendronate in the treatment of avaseular neerosis of the hip [J]. Rheumatology (Oxford).2002,41(3):346-347.
[105]Ichiseki T, Matsumoto T, Nishino M, et al. Oxidative stress and vascular permeability. In steroid-induced osteonecrosis model[J]. J Orthop Sci.2004, 9(5):509-515.
[106]Nishii T, Sugano N, Miki H, et al. Does alen. dronate p revent collapse in osteonecrosis of the femoral head [J]. Clin Orthop Relat Res,2006 (443): 273-279.
[107]Lai KA, Shen, WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis A randomized clinical study [J].J Bone Joint Surg(Am),2005 (87):2155-2159.
[108]党国际.云克治疗股骨头缺血坏死的临床分析[J].中原医刊,2007,34(6)：26-29.
[109]李鸿帅,张长青,股骨头坏死动物模型研究进展[J].国际骨科学杂志,2006,27(3)：173-175.
[110]K Miyanishi, T Yamamoto, T Irisa, et al. A highlow-density lipoproten cholesterol to high-density lipoproten cholestero ratio as a potential risk factor for cortieosteroid-induced osteonecrosis in rabbits [J]. Rheumatology, 2001,40(2):196-201.
[111]Miyanishi K, Yamamoto T, Irisa T, et al.Effects of different corticosteroids on the development of osteonecrosis in rabbits [J]. Rhcumato-logy (Oxford),2005,44(3):332-336.
[112]Cui Q, Wang GJ, Su CC, et al. The otto aufranc award.lovastatin prevents steroid induced adipoge nesisand osteonecrosis[J]. Clin Orthop,1997,344(1): 8-19.
[113]贺西京,毛履真,王坤正,等.肾上腺糖皮质激素引起股骨头缺血性坏死的机制实验研究[J].中华骨科杂志,1992,12(6)：440-443.
[114]李雄,袁浩,贝美莲,等.大剂量激素冲击应用与长期应用对股骨头坏死影响的动物实验[J].骨与关节损伤杂志,1999,14(4)：241-244.
[115]赵哲,王文波,李吉友,等.间断应用激素法制备兔股骨头缺血性坏死模型[J].中国实验动物学报,2008,16(4)：270-273.
[116]Yamatnato T.Corticosteroid enhances the experimental induction of osteonecrosis on rabbits with Shwartzman reaction[J]. Clin Orthop.1995, 316(3):235.
[117]刘万林,郭文通,李文琪,等.激素性股骨头缺血性坏死动物模型诱导[J].内蒙古医学院学报,1998,20(2)：71-74.
[118]赵金东,吕松岑,薛震,等.激素性股骨头坏死动物模型的建立与评价[J].中国骨肿瘤骨病,2007,6(4)：220-225.
[119]杨建平,王黎明,徐燕,等.单次低剂量脂多糖联合甲基强的松龙诱导股骨头坏死的实验研究[J].中国修复重建外科杂志,2008,22(3)：271-275.
[120]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[121]Matsui M, Saiti S, Ohzono K, et al. Experimental steroid-induced osteonecrosis in adult rabbits with hypersensitivity vasculitis[J]. clin Orthop,1992,277(1):61-72.
[122]李子荣,张念非,岳德波,等.激素性股骨头坏死动物模型的诱导和观察[J].中华外科杂志,1995,33(8)：485-487.
[123]胡志明,王海彬,李祖国,等.激素性股骨头坏死模型的建立及病理和影像学特征[J].广东药学院学报,2006,22(2)：181-184.
[124]张彦凌,马保安,张勇,等.马血清及不同结构皮质类固醇激素单独或联合应用对兔股骨头坏死产生的影响[J].中国临床康复,2006,10(15)：85-87.
[125]王伟,刘利英,王坤正,等.激素性股骨头坏死模型的建立及其发病机理的探讨[J].西安交通大学学报(医学版),2007,28(5)：544-547.
[126]马信龙,孙智超,马剑雄,等.改良型大鼠激素性股骨头坏死模型建立和相关评价[J].实用骨科杂志,2009,15(10)：760-763.
[127]程田,李月白,王义生.短期应用大剂量激素导致鸡股骨头坏死[J].郑州大学学报(医学版),2009,44(2)：285-287.
[128]李宇明.袁浩教授治疗股骨头缺血性坏死的学术思想和经验.全国股骨头无菌性坏死学术研讨会论文汇编(北京),1999：11.
[129]刘少军,袁浩.股骨头坏死的中医临床思路与方法探讨[J].中国医药学报,2002,17(1)：44-47.
[130]邓沂,张晓刚,任远,等.中医对股骨头坏死的认识[J].甘肃中医学院报,1988,巧(4)：54-56.
[131]陈卫衡,刘道兵,张洪美等.股骨头坏死的三期四型辨证思路[J].中国中医基础医学杂志,2003,9(12)：51-52.
[132]王峰,丁愕,李保泉.股骨头缺血性坏死的中医分型和治疗[J].中医正骨[J],2005,17(7)：23-24.
[132]齐振熙,曹阳.不同治法对激素性股骨头坏死血液流变学及血脂影响的实验研究[J].中国中医骨伤科杂志,2001,9(5)：30-31.
[133]洪加源,许书亮,阮景绰,等.复元散对激素性股骨头坏死脂代谢的影响.中医正骨,2001,13(4)6-8.
[134]徐传毅.袁浩教授以血瘀论治激素性股骨头坏死经验[J].中医药学刊,2003,21(2)：194-195
[135]徐传毅,何伟,李雄,等.从“瘀血”理论辨识股骨头坏死[J].中国中医基础医学杂志,2002,8(5)：18-19
[136]王杰林,殷玉芳,刘秀敏,等.小针刀配合中药康骨汤治疗股骨头坏死262例[J].中医外科杂志,2001,10(6)：24.
[137]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[138]刘少军,袁浩.股骨头坏死的中医临床思路与方法探讨[J].中国医药学报,2002,17(1)：44-47.
[139]陶海荣,张长青.激素性股骨头早期坏死的研究[J],中华国际医学杂志,2004,4(1)：63.
[140]田伟明,王文智,徐国华,等.骨复活汤和髓芯减压术治疗激素性早期股骨头坏死的临床研究[J].中国中医基础医学杂志,2005,11(1)：61-64.
[141]洪加源,许书亮,阮景绰,等.复元散对激素性股骨头坏死脂代谢的影响[J].中医正骨2001,13(4)：6.
[142]齐振熙,曹阳.不同治法对激素性股骨头坏死血液流变学及血脂影响的实验研究[J].中国中医骨伤科杂志2001,9(5)：30.
[143]李悦,筑红,邱德文,等.补肾化瘀方对激素性股骨头坏死大鼠脂代谢的影响[J].贵阳中医学院学报,2009,31
[144]周景华,王立春.活骨汤治疗股骨头缺血性坏死的实验研究.中医药研究2000；16(1)：45
[145]王国栋.骨舒合剂治疗激素性股骨头缺血坏死的实验研究[J].中医正骨,2003,15(10)：3.
[146]齐振熙,曹阳.活血化瘀中药防治激素性股骨头缺血性坏死的实验研究[J].现代康复,2001,5(12)：118-119.
[147]章建华,宋登峰,成立,等.骨健制剂对激素性股骨头坏死血液流变学的影响[J].中医正骨2008,20(4)：13-14.
[148]胡贺平,左松波,温翔.消蚀健骨汤对激素性股骨头坏死血液流变学的影响[J].河北医药,2008,30(1)：105.
[149]袁浩,方斌,何伟,等.生脉成骨胶囊治疗激素性股骨头坏死的实验研究[J].中医正骨,1999,11(8)：3.
[150]李雄,袁浩.袁浩教授对股骨头坏死中医药论治的学术思想[J].中国中医骨伤科杂志,1999,7(1)：61.
[151]徐传毅,黄涛,邹季,等.从血瘀论治激素性股骨头坏死的实验研究[J].中国中医骨伤科杂志,2000,8(4)：10.
[152]何伟,徐传毅,樊粤光,等.活血化瘀中药对激素性股骨头坏死血浆TXB2和6-keto-PGF1 α的影响.中国骨伤,2002；15(9)：531.
[153]王婷,宋怀燕,张文明.生骨片治疗激素性股骨头坏死的实验研究[J].实验动物科学与管理,2003；20(1)：20.
[154]肖鲁伟,童培建,赵万军,等.激素诱导的股骨头坏死与肾阳虚证之间的关系[J].中医正骨,1998,10(4)：3-4.
[155]吴承亮,季卫锋,俞索静,等.右归饮对家兔激素性股骨头坏死 骨髓脂肪化的影响[J].中医正骨,2006,18(7)：4-5.
[156]江中潮,邓友章,汪国友,等.仙灵骨葆胶囊治疗股骨头缺血性坏死30例的临床观察[J]中国中医骨伤科杂志,2006,14(增刊)：56-57.
[157]崔省珍,呼亚玲.仙灵骨葆胶囊对去卵巢大鼠骨代谢生化指标的影响[J]临床医药实践杂志,2007,16(4)：260-262.
[158]Yamamoto T, Irisa T, Sugioka Y, et al. Effects of pulse methylpredni solone on bone and marrow tissues:corticosteroid-induced osteonecrosis i n rabbits[J]. Arthritis Rheum,1997.40:2055-2064.
[159]Matsui M, Saito S, Ohzono K, et al. Experimental steroid induced osteon ecrosis inadult rabbits withh hypersensitivity vasculitis. Clin Orthop,19 92,277:61-72
[160]程田,李月白,王义生.短期应用大剂量激素导致鸡股骨头坏死[J],郑州大学学报(医学版),2009,44(2)：285-287.
[161]马信龙,孙智超,马剑雄,等.改良型大鼠激素性股骨头坏死模型建立和相关评价[J].实用骨科杂志,2009,15(10)：760-763.
[162]曹海利,白彬,孟巍.激素性股骨头缺血性坏死模型的动物实验研究[J].医学影 像学杂志,2008,18(2)：183-186.
[163]曾晓峰,赵建宁.肿瘤坏死因子受体和配体超家族的新成员[J].生命的化学[J],2003,23(4)：252-255.
[164]童培建,萧鲁伟,高根德.丹参治疗激素性股骨头无菌性坏死的实验研究[J].浙江医学,1997,19(2)：73.
[165]齐振熙,陈磊.活血化瘀法对激素性股骨头缺血坏死血液流变学的影响[J].福建中医学院学报,2006,16(6)：22.
[166]张弛,何洪阳,姚洪武,等.活血通络法对激素性股骨头坏死血液流变学的影响[J].中医正骨,2008,20(4)：15-16.
[167]赵润生,张一昕,苗冬雪,等.生地黄对血瘀模型大鼠血液流变性的影响[J].中药药理与临床,2006,22(3)：123.
[168]浦锡娟,徐凯琳.丹参的药理作用研究进展[J].临床医学工程,2009,16(8)：155
[169]柳永青.当归的化学成分与生物活性[J].航空航天医药,2009,20(11)：127.
[170]陈可冀,张之南,梁子钧.血瘀证与活血化瘀研究[M].上海科学技术出版社,1990：213-314.
[171]王海彬,赵咏芳,石印玉,等.中药对早期激素性股骨头坏死血管的影响[J].浙江中医药大学学报,2000,24(6)744-745.
[172]方微,秦彦文,王绿娅.何首乌总苷调血脂抗氧化的实验研究[J].中国药物应用与监测,2005,1：49-51.
[173]徐承水,王文房.何首乌提取物对大鼠血脂水平的影响[J].曲阜师范大学学报,2004,30(3)：85.
[174]NieSong-liu, XuXian-xiang, XiaLun-zhu. Effect of totals aponins of Codonopsis on blood lipid and nitricoxide level in experimental hyperlipemia rats[J]. Journal of Anhui TCM College,2002,21(4):40-41.
[175]张子臻.女贞子能降血糖、改善心肌供血[J].中医杂志,1998,9(9)：18.
[176]曹兰秀,周永学,顿宝生,女贞子总黄酮对高脂模型大鼠脂代谢的影响[J].第四军医大学学报,2009,30(20)：2129-2131.
[177]臧萍.泽泻的研究现状及展望[J].中国中医药远程现代教育,2009,7(6)：181.
[178]何雄伟,泽泻对健康受试者血脂影响的临床对照研究[J].重庆医科大学学报,2009,34(3)：376.
[179]叶希韵,张隆,沈菊,等.山楂叶总黄酮对糖尿病小鼠糖脂代谢能有效防治NASH的发展,能明显缓解NASH大鼠缺氧的影响[J].中草药,2005,36(11)H683-1686.
[180]纪影实,李红,杨世杰,等.山楂叶总黄酮对H2O2诱导PC12细胞凋亡的保护作用[J].中国药理学通报,2006,22(6)：760-762.
[181]周月英,吴延庆,张志宏.枸杞对人调脂作用的初步观察[J].临床经验荟 萃,2009,16(4)：42.
[182]刘梅洁,鞠大宏,赵宏艳,等.“肾主骨”的机理研究—左归丸含药血清对破骨细胞分化调控因子OPG、RANKL蛋白表达的影响[J].中国中医基础医学杂志,2009,15(3)：184-187.
[183]张晓刚,任远,王钢,等.生骨散对激素性股骨头坏死家兔血脂的影响[J].中国骨伤,2001,14(3)：148-149.
[184]张进,黄进,徐志伟.何首乌补肾作用的相关药理研究进展[J].中药新药与临床药理,2009,20(5)：486-498.
[185]高颖,房德敏.骨碎补黄酮类化合物的研究进展与开发前景[J].中草药,2009,402)：325-326.
[186]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J],中国中医骨伤科杂志,2003,11(6)：4-6.
[2]曾平,韦标方,展磊,等.何伟教授运用“治未病”理论指导股骨头坏死防治经验介绍[J].新中医,2009,41(1)：7.
[3]陈卫衡,许锐,欧彤文,等.中药预防激素性股骨头坏死临床初步研究[J],北京中医药,2008,27(10)：761-763.
[4]庞智辉.股骨头前外侧柱与激素性股骨头坏死预后和保魏疗效的相关性研究[J].广州中医药大学博士论文,2008.
[5]陈卫衡.股骨头坏死“痰瘀同治”的理论基础[J].江苏中医药,2008,40(5)：3-4.
[6]Pietrogrande V, Mastromarino R. Osteopatda prolungata trattamento corti sonico[J].Orthop Traum Appar Mat,1957,25:791-810.
[7]Jones JP, jr. Etiology and pathogenesis of Osteonecrosis[J]. Clin orthop, 1994,14:153.
[8]马在山.马氏中医治疗股骨头坏死[M].北京：人民卫生出版社,1996.116.
[9]刘铁钢,陈卫衡.非创伤性股骨头坏死的流行病学研究[J].当代医学,2008,14(24)：64-65.
[10]李子荣,孙伟,屈辉,等.皮质类固醇与骨坏死关系的临床研究[J].中华外科杂志2005,43(16)：1048-1053.
[11]陈卫衡,张强,刘道兵.SARS并发股骨头坏死的发病特点分析及临床意义[J].中国骨伤,2004,7(7)：338-340.
[12]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[13]Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy[J]. Diabetes Metab Res Rev,2003,19(Supp 11):2-8.
[14]Weinstein RS,Jilka RL, Parfitt AM, etal. Inhibition of osteoblastogenesis and Prorootion of apoptosis of osteoblasts and osteoeytes by glueeeorti-coids. Potential mechanisms of their deleterious efects on bone[J].J Clin Invest,1998,102(2):274-282.
[15]Hemigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem cell pool in the proximal femur in corticosteroid-induced osteonecrosis[J]. J Bone Joint Surs Br.1999,81(2):349-355.
[16]LiX, Jin L, Cui Q,et al. Steroid effects on osteogenesis through mesenc hymal cell gene expression[J]. Osteoporos Int.2004,15:1.
[17]Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis[J]. Clin Orthop.2000,370:295-310.
[18]Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glu cocorticoid-induced osteonecrosis of the hip[J].J Clin Endocrinol Metab. 2000,85 (8):2907-2912.
[19]曾小军,杨述华,禹志宏.辛伐他汀联合阿仑磷酸钠预防兔激素性股骨头坏死[J],郧阳医学院学报,2009,28(3)：237-243.
[20]黄昌林,杨卫强.兔激素性股骨头坏死早期骨组织细胞功能改变及外敷中药的治疗作用观察[J].解放军医学杂志,2009,34(5)：501-503.
[21]Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine t hat regulates osteoclast differentiation and activation[J]. Cell,1998,93: 165-176
[22]Hofbauer LC, Gorl F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocoticoid-induced osteoporosis[J]. Endoerinologi,1999,140:4382-4389.
[23]王岩,迟志永,韩纲.激素性骨坏死骨质丢失与骨保护蛋白表达的相关研究[J].中华外科杂志,2002,7：534-537.
[24]王建忠,王坤正,时志斌,等.长期应用糖皮质激素对大鼠股骨头骨组织OPG/RANKL mRNA表达的影响[J].西安交通大学学报,2008,29(6)：630-632.
[25]Jones JP. Intravaseular coagulation and osteonecrosis[J]. Clin Orthop, 1992,277:41.
[26]Kawai K, Tamaki A, Hirohata H, et al. Steroid2induced accumulation o f lipid in the osteocytes of the rabbit femoral head. A histochemical an d electron microscop ic study [J].J Bone Joint Surg Am,1985,67(5):755-76 3.
[27]薛元锁,时述山,李亚非,等.激素性股骨头坏死病程中骨形态发生蛋白-2的改变及意义[J].中华实验外科杂志,2000,17(5)：455-456.
[28]周谋望,秦建中,刘志雄,等.降脂药物防治激素所致股骨头骨细胞损害的实验研究[J].中华医学杂志,1996,76(1)：13-15.
[29]周谋望,秦建中,朱盛修.激素导致股骨头骨细胞损害的研究[J].中华实验外科杂志,1994,11(2)：89-90.
[30]吴洪娟,郭文君,王亦进,等.激素诱发兔股骨头坏死的组织学及超微结构观察[J].解剖科学进展,2003,9(1)：23-24.
[31]Yin L, LI YB, Wang YS. Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures:mechanism of steroid-induced osteonecrosis[J]. Chin Med J,2006,119(7):581-588.
[32]张义福,刘建,孟国林,等.兔激素性股骨头坏死病程中肝脂肪酶改变的意义[J].第四军医大学学报,2006,27(8)：737-740.
[33]Asano T, Takahashi KA, Fujioka M, Inoue S, Satomi Y, Nishino H, Tanaka T, Hirota Y, Takaoka K, Nakajima S, Kubo T Genetic analysis of steroid-induced osteonecrosis of the femoral head [J]. Orthop Sci.2003,8(3):329-333.
[34]刘德宝,卜海富,桂斌捷.大剂量激素诱导建立兔股骨头缺血性坏死模型[J].中国组织工程研究与临床康复,2009,13(2)：284-287.
[35]童培建,肖鲁伟,季卫锋,等.脂质代谢及破骨细胞活性在激素性股骨头坏死塌陷发生过程中的作用研究[J].中国骨伤,2009,22(2)：110-113
[36]Jones Jp. Fat embolisms, intravascular coagulation, and osteonecrosis[J]. Clin Othop,1993,292:294-308
[37]Jones LC, Mont MA, Le TB,et al. Procoagulants and osteonecrosis[J]. Rheu matol,2003,30(4):783.
[38]KoromPilias AV,Ortel TL, Uthaniak JR. Coagulation abnormalities in Patients with hip osteonecrosis[J]. orthop Clin North Am.2004,35(3):265-271.
[39]Wolf Drescher, Karen P, Weigert, et al. Fermoral head blood flow reducti on and hypercoagulablitity under 24 hmegadose steroidtreatment in pigS [J].J orthopaedic Research.2004,22:501-508.
[40]Tsantarliotou MP, Taitzoglou IA, Goulas P, et al. Dexamethasone reduees acrosin activity of ram spermatozoa[J]. Andrologia.2002,34(3):188-193.
[41]Halleux CM, Declerek PJ, Tran SL,et al. Hormonal control of plasminogen activator in hibitor-1 gene expression and produecion in human adipose tissue:stimulation by glucocorticoids and inhibition by catecholamines[J]. J Clin Endocrinol Metab.1999,84(11):4097-4105.
[42]Shimojo M, Miyachi Y. Hyperlipidemia and glucocorticoid[J]. Nippon Rins ho.2001,59 Supp13:220-222.
[43]Perera M, Sattar N, Petrie JR, et al. The effects of transdermal estradi ol incombination with oral norethisterone on lipoproteins, coagulation, an d endothelial markers in postmenopausal Women with type 2 diabetes:arand omized, plaeebo-controlled study[J].J Clin Endocrinol Metab.2001,86(3):11 40-1143.
[44]Ichiseki T, Matsumoto T,Nishino M, et al.oxidative stress and vascular permeability in steroid-induced osteonecrosis model[J].J orthop Sci.2004, 9(5):509-515.
[45]Wallwork CJ, Parks DA, Sehmid-Sehonbein GW. Xanthine oxidase activity i n the dexamethasone-induced hypertensive rat[J]. Microvasc Res.2003,66(1): 30-37.
[46]Vogt CJ, Schmid-Schonbein GW. Microvascular endothelial cell death and rarefaction in the gluecocorticoid-induced hypertensive rat[J]. Mierocir culation.2001,8(2):129-139.
[47]李子荣,孙伟,屈辉,等.皮质类固醇与骨坏死关系的临床研究.中华外科杂志[J],2005,43(16)：1048-1053
[48]Asano T, Takahashi KA, Fujioka M, et al.ABCBI C3435T and G2677T/A Po lymorphism decreased the risk for steroid-induced osteonecrosis of the f emoral head after kidney transplantation[J]. Pharmacogenetics.2003,13(1 1):675-682.
[49]Zalavras CG, Vartholomatos G, Dokou E, Malizos KN Genetic background of osteonecrosis:associated with thrombophilic mutations?[J]. Clin Orth op.2004,422:251-255.
[50]Ferrari, P; Sehroeder V;Anderson S et al. Association of plasminogen aetivator inhibitor-1 genotyPe with avaseular osteonecrosis in steroid-treated renal allograft recipients[J]. TransPlantation.2002,74(8):1147-11 52.
[51]Bjorkman A, Svensson PJ, Hillarp A, et al. Faetor V leiden and Prothrombin genemution:risk factors for osteonecrosis of the femoral head in adults[J]. ClinorthoP.2004,425:168-172.
[52]Murata M. Genetic polymorphisms assoeiated with thrombotic disorders in Japanese poPulation [J]. Fibrinolyis & Proteolysis.2000,14:155.
[53]Asano T, Takallashi KA, Fujioka M. Relationship between postrenal tra nsplant osteonecrosis of the feromal head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects [J]. T ransplantatation.2004,77(2):220-225.
[54]何伟,李可大.激素性股骨头坏死的遗传易感性研究[J].中国骨与关节外科,3009.2(4)：284-289.
[55]Ueo T, Tsutsumi Syamamuro T, et al. Biomechanical aspect of the development of aseptic necrosis of the femoral head[J].Arch Orthop Trauma Surg,1985, 104(3):145-149.
[56]Mihara K,Hiranmo T. Standing is a causative factor in osteonecrosis o f the femoral head in growing rats[j].Joumal of pediatric orthopaedics,1 998,18 (5):665-669.
[57]Iwasaki K, Hirano T, Sagara K, et al. Idiopathic necrosis of the femoral Epiphyseal nucleus in rats[J].Clin Orthop,1992,31-40.
[58]Suehiro M, Hirano T, Mihara K, et al.Etiologic factors in femoral head Osteonecrosis in growing rats[J]. OrthopSci,2000,5:52-6.
[59]王金熙,董天华,陈贤志,等.实验性股骨头缺血性坏死修复过程的生物力学研究[J].中华外科杂志,1993,31(6)：374
[60]Magnussen RA, Guilak F, Vail TP, Cartilage degenration in post-collapse case of osteonecrosis of the human femoral head:altered mechanical properties in tension compression and shear[J], J Orthop Res,2005,23:576-583.
[61]Jones JP. Intravascular coagulation and osteonecrosis[J]. Clin Or. thop, 1992,277:41.
[62]Saito S, Ohzono K, Ono K. Early arteriopathy and postulated pathogenesis of the femoral head[J]. Clin Orthop,1992,277:98.
[63]Atsumi T, Yoshikatsr K. Role of blood supply of the femoral head in the pathogenesis of idiopathic osteonecrosis[J]. Clin Orthop,1992,277:22.
[64]Wang GJ, Cui Q. The Pathogenesis Of Steroid-Induced Osteonecrosis and the Effect of Lipid Clearing Agents on this Mechanism [A]Ur baniak JR, Jones Jr JP. Osteonecrosis. Vo122. Rosemont. IL American. Orthopaedic Association and American Academy of Orthopaedic Surgeons.1997,22:159-166.
[65]Hirano K, Tsutsui H, Sugioka Y, et al. Histopathologic alterations of retinacular vessels and osteonecrosis[J]. Clin Orthop,1997,342:192.
[66]Nishimura T, Matsumoto T, Nishino M, et al. Histopatbologic study of veins in steroid treated rabbits[J]. Clin Orthop,1997,334:37.
[67]郑召民,董大华.非刨伤性骨坏死血管内凝血学说研究的进展[J].中华骨科杂志,1998,18(10)：627.
[68]姚永东,王国毓,杨毓华,等.激素性股骨头坏死动物血液流变学的观察[J].中医正骨,2000,12(4)：6-7.
[69]李峻辉,宁亚功,叶建红,等.激素性股骨头坏死家兔血液流变学及血脂观察[J].云南医药,2003,24(2)：82-84.
[70]胡长根,陈君长,刘强,等.激素对股骨头微血管及组织细胞的影响[J].中华骨科杂志,2004,24(6)：359.
[71]洪嵩,张天宏.非创伤性股骨头坏死模型的血液流变学及脂质代谢[J].遵义医 学院学报,2009,32(2)：136-138.
[72]胡长根,陈君长,贺西京,等.激素性股骨头坏死与血液流变学变化的关系[J].西安交通大学学报(医学版),2003,24(6)：595-598.
[73]李月白.激素诱导骨髓基质细胞成脂分化的实验研究[J].中华骨科杂志,1999,19(11)：687-689.
[74]Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin lig and and inhibition of osteoprotegerin production by glucocorticoids in h uman osteoblastic lincage cells:potential paracrine mechanisms of glucoc orticoid-induced osteopomsis[J]. Endocrinology,1999,140:4382-4389.
[75]童培建,肖鲁伟,季卫锋,等.脂质代谢及破骨细胞活性在激素性股骨头坏死塌陷发生过程中的作用研究[J].中国骨伤,2009,22(2)：110-113.
[76]Cui Q, Wang CJ, Balian C. Steroid induced adipogenesis pluripotential cell line from bone marrow[J]. J Bone Joint Surg(Am),1997,79:1054-1063.
[77]0reffo RO, Virdi AS, Triffiu JT. Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures [J]. Eur J Cell Biol, 1997,74:251-261.
[78]薛元锁,时述山,李亚非,等.激素性股骨头坏死病程中骨形态发生蛋白-2的改变及其意义[J].中华实验外科杂志,2000,17(5)：455.
[79]Hemigou P, Beaujean F Treatment of osteonecrosis with autologous bone marrow grafting [J]. Clin Orthop.2002,405:14-23.
[80]Gang ji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells [J]. A pilot study. J Bone Joint Surg Am.2004,86-A(6):1153-1160.
[81]Valentin-Opran A, Wozney J, Csimma C, et al. Clinical evaluation of recombinant human bone morphogenetic protein-2 [J]. Clin Orthop.2002,395: 110-120.
[82]梅荣成,杨述华,杨操,等.钛合金支撑架结合自体骨和DBM治疗股骨头坏死[J].中国矫形外科杂志,2006,14(7)：509-51.
[83]LiX, Cui Q, Kao C, Wang GJ, Balian Glovastatin inhibits adipogenic an d stimulates osteogenic differentiation by suppressing PRARgamma2 and in creasing Cbfal/Runx2 cxpression in bone marrow mesenehymal cell cultures [J]. Bone.2003,33(4):652-659.
[84]Cui Q, Wang GJ, Su CC, Balian G The Otto Aufranc Award. Lovastatin pr events steroid induced adipogenesis and osteonecrosis[J]. Clin Orthop.1 997,344:8-19.
[85]Pritchett JW Statin therapy decreases the risk of osteonecrosis in p atients receiving steroids [J].Clin Orthop.2001,386:173-178.
[86]曾小军,杨述华,禹志宏.辛伐他汀联合阿仑磷酸钠预防兔激素性股骨头坏死[J],郧阳医学院学报,2009,28(3)：237-243.
[87]王卫东,廖文胜,王义生.辛伐他汀预防激素性股骨头坏死的实验研究[J].郑州大学学报(医学版),2004,39(3)：473-475.
[88]周谋望,秦建中,刘志雄,等.降脂药物防治激素所致股骨头骨细胞损害的实验研究[J].中华医学杂志,1996,76(1)：13-16.
[89]Glueck CJ, Freiberg RA, Wang P. Role of thrombosis in osteoneerosis[J]. CurrHematol Rep.2003,2(5):417-422.
[90]Glueek CJ, Freiberg RA, Fontaine RN, et al. Anticoagulant therapy fo r osteonecrosis associated with heritable hypofibrinolysis and thromboph ilia [J] Expert Opin Investig Drugs.2001,10(7):1309-1316.
[91]Norman D, Miller Y, Sabo E, et al. The effects of enoxaparin on the reparative Processes in experimental osteonecrosis of the femoral head of the rat [J]. APMIS.2002,110(3):221-228.
[92]刘万林,郭文通,李文琪,等.抗凝改善骨内微循环治疗激素性股骨头缺血性坏死的初步观察[J1.内蒙古医学院学报,1999,21(4)：235-256.
[93]廖文胜,王义生,高远,等.激素性股骨头坏死发病机制及藻酸双酯钠的干预作用[J].河南医药信息,2001,9(10)：1-3.
[94]李卫哲,李景南,张新.抗凝药物预防激素所致股骨头坏死[J].吉林大学学报(医学版),2003,29(4)：475-476.
[95]Masuhara K, Nakata K, Yamasaki S, et al. Involvement of plateletN activation in experimental osteonecrosis in rabbits[J]. Int J Exp Pathol,2001,82(5): 303-308.
[96]李卫哲,李景南,张新.抗凝药物预防激素所致股骨头坏死[J].吉林大学学报(医学版),2003,29(4)：475-476.
[97]Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid Induced oste onecrosis of femoral head in systemic lupuserythematosus by anticoagulan t[J]. Lupus,2006,15(6):354-357.
[98]Lauber S. High energy extracorporeal shockwave therapy in femur head necrosis[J].Z Orthop Ihre Grenzgeb.2000,138(5):3-4.
[99]Ludwig J, Lauber S, Lauber HJ, et al. High-energy shock wave treatment of femoral head necrosis in adults [J].Clin Orthop.2001,387:119-126.
[100]Trock DH. Electromagnetic fields and magnets. Investigational treatment for musculoskeletal disorders [J], Rheum Dis Clin North Am.2000,26(1):51-62.
[101]Kim HJ. Comrnent on:Hyperbaric oxygen therapy as a treatment for st age-Iavascular necrosis of the femoral head [J]. J Bone Joint Surg Br.20 04,86(1):150-151.
[102]Reis ND, Schwartz 0, Militianu D, et al. Hyperbaric oxygen therapy as a treatment for stage-I avaseular necrosis of the femoral head [J]. J Bone Joint Surg Br.2003,85(3):371-375.
[103]Seber S, Omerogiu H, Cetlnkanat H, et al. The efficacy of pulsed elect romagnetic fields used alone in the treatment of femoral head osteonecro sis:a report of two cases [J]. Acta Orthop Traumatol Turc.2003,37(5):41 0-413.
[104]Agarwala S, Sule A, Pai BU, et al. Alendronate in the treatment of avaseular neerosis of the hip [J]. Rheumatology (Oxford).2002,41(3):346-347.
[105]Ichiseki T, Matsumoto T, Nishino M, et al. Oxidative stress and vascular permeability. In steroid-induced osteonecrosis model[J]. J Orthop Sci.2004, 9(5):509-515.
[106]Nishii T, Sugano N, Miki H, et al. Does alen. dronate p revent collapse in osteonecrosis of the femoral head [J]. Clin Orthop Relat Res,2006 (443): 273-279.
[107]Lai KA, Shen, WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis A randomized clinical study [J].J Bone Joint Surg(Am),2005 (87):2155-2159.
[108]党国际.云克治疗股骨头缺血坏死的临床分析[J].中原医刊,2007,34(6)：26-29.
[109]李鸿帅,张长青,股骨头坏死动物模型研究进展[J].国际骨科学杂志,2006,27(3)：173-175.
[110]K Miyanishi, T Yamamoto, T Irisa, et al. A highlow-density lipoproten cholesterol to high-density lipoproten cholestero ratio as a potential risk factor for cortieosteroid-induced osteonecrosis in rabbits [J]. Rheumatology, 2001,40(2):196-201.
[111]Miyanishi K, Yamamoto T, Irisa T, et al.Effects of different corticosteroids on the development of osteonecrosis in rabbits [J]. Rhcumato-logy (Oxford),2005,44(3):332-336.
[112]Cui Q, Wang GJ, Su CC, et al. The otto aufranc award.lovastatin prevents steroid induced adipoge nesisand osteonecrosis[J]. Clin Orthop,1997,344(1): 8-19.
[113]贺西京,毛履真,王坤正,等.肾上腺糖皮质激素引起股骨头缺血性坏死的机制实验研究[J].中华骨科杂志,1992,12(6)：440-443.
[114]李雄,袁浩,贝美莲,等.大剂量激素冲击应用与长期应用对股骨头坏死影响的动物实验[J].骨与关节损伤杂志,1999,14(4)：241-244.
[115]赵哲,王文波,李吉友,等.间断应用激素法制备兔股骨头缺血性坏死模型[J].中国实验动物学报,2008,16(4)：270-273.
[116]Yamatnato T.Corticosteroid enhances the experimental induction of osteonecrosis on rabbits with Shwartzman reaction[J]. Clin Orthop.1995, 316(3):235.
[117]刘万林,郭文通,李文琪,等.激素性股骨头缺血性坏死动物模型诱导[J].内蒙古医学院学报,1998,20(2)：71-74.
[118]赵金东,吕松岑,薛震,等.激素性股骨头坏死动物模型的建立与评价[J].中国骨肿瘤骨病,2007,6(4)：220-225.
[119]杨建平,王黎明,徐燕,等.单次低剂量脂多糖联合甲基强的松龙诱导股骨头坏死的实验研究[J].中国修复重建外科杂志,2008,22(3)：271-275.
[120]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[121]Matsui M, Saiti S, Ohzono K, et al. Experimental steroid-induced osteonecrosis in adult rabbits with hypersensitivity vasculitis[J]. clin Orthop,1992,277(1):61-72.
[122]李子荣,张念非,岳德波,等.激素性股骨头坏死动物模型的诱导和观察[J].中华外科杂志,1995,33(8)：485-487.
[123]胡志明,王海彬,李祖国,等.激素性股骨头坏死模型的建立及病理和影像学特征[J].广东药学院学报,2006,22(2)：181-184.
[124]张彦凌,马保安,张勇,等.马血清及不同结构皮质类固醇激素单独或联合应用对兔股骨头坏死产生的影响[J].中国临床康复,2006,10(15)：85-87.
[125]王伟,刘利英,王坤正,等.激素性股骨头坏死模型的建立及其发病机理的探讨[J].西安交通大学学报(医学版),2007,28(5)：544-547.
[126]马信龙,孙智超,马剑雄,等.改良型大鼠激素性股骨头坏死模型建立和相关评价[J].实用骨科杂志,2009,15(10)：760-763.
[127]程田,李月白,王义生.短期应用大剂量激素导致鸡股骨头坏死[J].郑州大学学报(医学版),2009,44(2)：285-287.
[128]李宇明.袁浩教授治疗股骨头缺血性坏死的学术思想和经验.全国股骨头无菌性坏死学术研讨会论文汇编(北京),1999：11.
[129]刘少军,袁浩.股骨头坏死的中医临床思路与方法探讨[J].中国医药学报,2002,17(1)：44-47.
[130]邓沂,张晓刚,任远,等.中医对股骨头坏死的认识[J].甘肃中医学院报,1988,巧(4)：54-56.
[131]陈卫衡,刘道兵,张洪美等.股骨头坏死的三期四型辨证思路[J].中国中医基础医学杂志,2003,9(12)：51-52.
[132]王峰,丁愕,李保泉.股骨头缺血性坏死的中医分型和治疗[J].中医正骨[J],2005,17(7)：23-24.
[132]齐振熙,曹阳.不同治法对激素性股骨头坏死血液流变学及血脂影响的实验研究[J].中国中医骨伤科杂志,2001,9(5)：30-31.
[133]洪加源,许书亮,阮景绰,等.复元散对激素性股骨头坏死脂代谢的影响.中医正骨,2001,13(4)6-8.
[134]徐传毅.袁浩教授以血瘀论治激素性股骨头坏死经验[J].中医药学刊,2003,21(2)：194-195
[135]徐传毅,何伟,李雄,等.从“瘀血”理论辨识股骨头坏死[J].中国中医基础医学杂志,2002,8(5)：18-19
[136]王杰林,殷玉芳,刘秀敏,等.小针刀配合中药康骨汤治疗股骨头坏死262例[J].中医外科杂志,2001,10(6)：24.
[137]何伟.糖皮质激素与股骨头坏死[J].中国处方药.2004,3(24)：22-26.
[138]刘少军,袁浩.股骨头坏死的中医临床思路与方法探讨[J].中国医药学报,2002,17(1)：44-47.
[139]陶海荣,张长青.激素性股骨头早期坏死的研究[J],中华国际医学杂志,2004,4(1)：63.
[140]田伟明,王文智,徐国华,等.骨复活汤和髓芯减压术治疗激素性早期股骨头坏死的临床研究[J].中国中医基础医学杂志,2005,11(1)：61-64.
[141]洪加源,许书亮,阮景绰,等.复元散对激素性股骨头坏死脂代谢的影响[J].中医正骨2001,13(4)：6.
[142]齐振熙,曹阳.不同治法对激素性股骨头坏死血液流变学及血脂影响的实验研究[J].中国中医骨伤科杂志2001,9(5)：30.
[143]李悦,筑红,邱德文,等.补肾化瘀方对激素性股骨头坏死大鼠脂代谢的影响[J].贵阳中医学院学报,2009,31
[144]周景华,王立春.活骨汤治疗股骨头缺血性坏死的实验研究.中医药研究2000；16(1)：45
[145]王国栋.骨舒合剂治疗激素性股骨头缺血坏死的实验研究[J].中医正骨,2003,15(10)：3.
[146]齐振熙,曹阳.活血化瘀中药防治激素性股骨头缺血性坏死的实验研究[J].现代康复,2001,5(12)：118-119.
[147]章建华,宋登峰,成立,等.骨健制剂对激素性股骨头坏死血液流变学的影响[J].中医正骨2008,20(4)：13-14.
[148]胡贺平,左松波,温翔.消蚀健骨汤对激素性股骨头坏死血液流变学的影响[J].河北医药,2008,30(1)：105.
[149]袁浩,方斌,何伟,等.生脉成骨胶囊治疗激素性股骨头坏死的实验研究[J].中医正骨,1999,11(8)：3.
[150]李雄,袁浩.袁浩教授对股骨头坏死中医药论治的学术思想[J].中国中医骨伤科杂志,1999,7(1)：61.
[151]徐传毅,黄涛,邹季,等.从血瘀论治激素性股骨头坏死的实验研究[J].中国中医骨伤科杂志,2000,8(4)：10.
[152]何伟,徐传毅,樊粤光,等.活血化瘀中药对激素性股骨头坏死血浆TXB2和6-keto-PGF1 α的影响.中国骨伤,2002；15(9)：531.
[153]王婷,宋怀燕,张文明.生骨片治疗激素性股骨头坏死的实验研究[J].实验动物科学与管理,2003；20(1)：20.
[154]肖鲁伟,童培建,赵万军,等.激素诱导的股骨头坏死与肾阳虚证之间的关系[J].中医正骨,1998,10(4)：3-4.
[155]吴承亮,季卫锋,俞索静,等.右归饮对家兔激素性股骨头坏死 骨髓脂肪化的影响[J].中医正骨,2006,18(7)：4-5.
[156]江中潮,邓友章,汪国友,等.仙灵骨葆胶囊治疗股骨头缺血性坏死30例的临床观察[J]中国中医骨伤科杂志,2006,14(增刊)：56-57.
[157]崔省珍,呼亚玲.仙灵骨葆胶囊对去卵巢大鼠骨代谢生化指标的影响[J]临床医药实践杂志,2007,16(4)：260-262.
[158]Yamamoto T, Irisa T, Sugioka Y, et al. Effects of pulse methylpredni solone on bone and marrow tissues:corticosteroid-induced osteonecrosis i n rabbits[J]. Arthritis Rheum,1997.40:2055-2064.
[159]Matsui M, Saito S, Ohzono K, et al. Experimental steroid induced osteon ecrosis inadult rabbits withh hypersensitivity vasculitis. Clin Orthop,19 92,277:61-72
[160]程田,李月白,王义生.短期应用大剂量激素导致鸡股骨头坏死[J],郑州大学学报(医学版),2009,44(2)：285-287.
[161]马信龙,孙智超,马剑雄,等.改良型大鼠激素性股骨头坏死模型建立和相关评价[J].实用骨科杂志,2009,15(10)：760-763.
[162]曹海利,白彬,孟巍.激素性股骨头缺血性坏死模型的动物实验研究[J].医学影 像学杂志,2008,18(2)：183-186.
[163]曾晓峰,赵建宁.肿瘤坏死因子受体和配体超家族的新成员[J].生命的化学[J],2003,23(4)：252-255.
[164]童培建,萧鲁伟,高根德.丹参治疗激素性股骨头无菌性坏死的实验研究[J].浙江医学,1997,19(2)：73.
[165]齐振熙,陈磊.活血化瘀法对激素性股骨头缺血坏死血液流变学的影响[J].福建中医学院学报,2006,16(6)：22.
[166]张弛,何洪阳,姚洪武,等.活血通络法对激素性股骨头坏死血液流变学的影响[J].中医正骨,2008,20(4)：15-16.
[167]赵润生,张一昕,苗冬雪,等.生地黄对血瘀模型大鼠血液流变性的影响[J].中药药理与临床,2006,22(3)：123.
[168]浦锡娟,徐凯琳.丹参的药理作用研究进展[J].临床医学工程,2009,16(8)：155
[169]柳永青.当归的化学成分与生物活性[J].航空航天医药,2009,20(11)：127.
[170]陈可冀,张之南,梁子钧.血瘀证与活血化瘀研究[M].上海科学技术出版社,1990：213-314.
[171]王海彬,赵咏芳,石印玉,等.中药对早期激素性股骨头坏死血管的影响[J].浙江中医药大学学报,2000,24(6)744-745.
[172]方微,秦彦文,王绿娅.何首乌总苷调血脂抗氧化的实验研究[J].中国药物应用与监测,2005,1：49-51.
[173]徐承水,王文房.何首乌提取物对大鼠血脂水平的影响[J].曲阜师范大学学报,2004,30(3)：85.
[174]NieSong-liu, XuXian-xiang, XiaLun-zhu. Effect of totals aponins of Codonopsis on blood lipid and nitricoxide level in experimental hyperlipemia rats[J]. Journal of Anhui TCM College,2002,21(4):40-41.
[175]张子臻.女贞子能降血糖、改善心肌供血[J].中医杂志,1998,9(9)：18.
[176]曹兰秀,周永学,顿宝生,女贞子总黄酮对高脂模型大鼠脂代谢的影响[J].第四军医大学学报,2009,30(20)：2129-2131.
[177]臧萍.泽泻的研究现状及展望[J].中国中医药远程现代教育,2009,7(6)：181.
[178]何雄伟,泽泻对健康受试者血脂影响的临床对照研究[J].重庆医科大学学报,2009,34(3)：376.
[179]叶希韵,张隆,沈菊,等.山楂叶总黄酮对糖尿病小鼠糖脂代谢能有效防治NASH的发展,能明显缓解NASH大鼠缺氧的影响[J].中草药,2005,36(11)H683-1686.
[180]纪影实,李红,杨世杰,等.山楂叶总黄酮对H2O2诱导PC12细胞凋亡的保护作用[J].中国药理学通报,2006,22(6)：760-762.
[181]周月英,吴延庆,张志宏.枸杞对人调脂作用的初步观察[J].临床经验荟 萃,2009,16(4)：42.
[182]刘梅洁,鞠大宏,赵宏艳,等.“肾主骨”的机理研究—左归丸含药血清对破骨细胞分化调控因子OPG、RANKL蛋白表达的影响[J].中国中医基础医学杂志,2009,15(3)：184-187.
[183]张晓刚,任远,王钢,等.生骨散对激素性股骨头坏死家兔血脂的影响[J].中国骨伤,2001,14(3)：148-149.
[184]张进,黄进,徐志伟.何首乌补肾作用的相关药理研究进展[J].中药新药与临床药理,2009,20(5)：486-498.
[185]高颖,房德敏.骨碎补黄酮类化合物的研究进展与开发前景[J].中草药,2009,402)：325-326.
[186]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J],中国中医骨伤科杂志,2003,11(6)：4-6.